SiliconBeat

Map Pharmaceuticals, the Mountain View development stage pharmaceutical company, said today that the initial Phase 3 clinical trial for budesonide for the potential treatment of children with asthma did not meet expectations in either of the doses evaluated when compared with a placebo.

The study included 360 children with asthma, 12-months to eight years of age, who were treated in two different doses twice a day over a 12-week period.

One piece of good news was that review of the data showed no serious side effects. The company said that patients continue to be treated in a 52-week safety study to collect long-term safety data.

“We and our partner, AstraZeneca, are conducting further analyses of these data to determine appropriate next steps going forward for the program,” said Map Chief Executive Timothy Nelson in a statement.